RanBP1: A Potential Therapeutic Target for Cancer Stem Cells in Lung Cancer and Glioma
Yeon-Jee Kahm1,2, In-Gyu Kim1,2, Rae-Kwon Kim1,2
1Department of Radiation Biology, Environmental Safety Assessment Research Division, Korea Atomic Energy Research Institute, Yuseong-gu, Daejeon 34057, Republic of Korea.
International Journal of Molecular Sciences
|April 13, 2023
Summary
Ran-binding protein 1 (RanBP1) is highly expressed in cancer stem cells, driving resistance to treatment and promoting metastasis. Targeting RanBP1 could offer a new strategy to suppress these difficult-to-treat cancer cells.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Cancer stem cells (CSCs) present a significant challenge in cancer therapy due to their resistance and self-renewal capabilities.
- Identifying novel therapeutic targets to specifically eliminate CSCs is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the role of Ran-binding protein 1 (RanBP1) as a potential therapeutic target in cancer stem cells.
- To explore the association between RanBP1 expression and key CSC characteristics, including radioresistance, metastasis, and the cancer microenvironment.
Main Methods:
- Assessed RanBP1 expression levels in lung cancer stem cells (LCSCs) and glioma stem cells (GSCs).
- Correlated RanBP1 expression with CSC markers, regulators, patient prognosis, radioresistance, epithelial-mesenchymal transition (EMT), and cytokine IL-18 modulation.
- Evaluated the impact of RanBP1 on cell motility and the cancer microenvironment.
Main Results:
- High RanBP1 expression was observed in LCSCs and GSCs, correlating with CSC markers and poor patient prognosis.
- RanBP1 was found to regulate CSC radioresistance, EMT, and cell motility.
- RanBP1 modulates the cancer microenvironment by regulating the pro-tumorigenic cytokine IL-18.
Conclusions:
- RanBP1 is a key regulator in LCSCs and GSCs, influencing critical cancer-promoting processes.
- RanBP1 represents a promising novel therapeutic target for overcoming CSC-mediated treatment resistance and metastasis.
Related Concept Videos
01:20The Retinoblastoma Gene
4.2K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.2K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K